Meeting
2023 ASCO Annual Meeting
RT-PACE: Phase I/II study of adjuvant whole pelvic hypofractionated radiotherapy for non-metastatic cervical and endometrial cancer.
Authors
Christina H. Son
University of Chicago, Chicago, IL
Christina H. Son , Gita Suneja , Jonathan Chipman , John Cursio , Hania A Al-Hallaq , David K. Gaffney , Yasmin Hasan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT04683653
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS5631)
DOI
10.1200/JCO.2023.41.16_suppl.TPS5631
Abstract #
TPS5631
Poster Bd #
316b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes during pelvic radiation therapy: A secondary analysis on sexual function from NRG-RTOG 1203.
First Author: Kelsey L Corrigan
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA.
First Author: Jones T. Nauseef
Poster
2022 ASCO Genitourinary Cancers Symposium
Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: A secondary analysis of the NRG oncology RTOG 0415 randomized clinical trial.
First Author: David James Carpenter
Poster
2020 Genitourinary Cancers Symposium
Eight-year outcomes of a phase III randomized trial of conventional versus hypofractionated high-dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): Update from the CHHiP Trial.
First Author: David P. Dearnaley